ProPhase Labs, Inc. Increase (Decrease) in Assets Held-for-sale
ProPhase Labs, Inc. (PRPH) reported Increase (Decrease) in Assets Held-for-sale of -$22.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-26.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAssetsHeldForSale · last filed 2020-03-26
- ProPhase Labs, Inc. increase (decrease) in assets held-for-sale for the quarter ending 2018-12-31 was $0.00.
- ProPhase Labs, Inc. increase (decrease) in assets held-for-sale for the quarter ending 2018-09-30 was $0.00.
- ProPhase Labs, Inc. increase (decrease) in assets held-for-sale for the quarter ending 2018-06-30 was $0.00.
- ProPhase Labs, Inc. increase (decrease) in assets held-for-sale for the quarter ending 2018-03-31 was -$22.00K, a 103.15% decline year-over-year.
- ProPhase Labs, Inc. increase (decrease) in assets held-for-sale for fiscal 2018 was -$22.00K, a 200.00% decline from fiscal 2017.
- ProPhase Labs, Inc. increase (decrease) in assets held-for-sale for fiscal 2017 was $22.00K.
| Period end | Increase (Decrease) in Assets Held-for-sale 3 month | Increase (Decrease) in Assets Held-for-sale 6 month | Increase (Decrease) in Assets Held-for-sale 9 month | Increase (Decrease) in Assets Held-for-sale 9 month as first filed | Increase (Decrease) in Assets Held-for-sale 12 month |
|---|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $0.00 derived: sum of 2 quarters · filed 2020-03-26 | $0.00 derived: sum of 3 quarters · filed 2020-03-26 | -$22.00K 10-K · filed 2020-03-26 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | -$22.00K 10-Q · filed 2019-11-12 | -$22.00K derived: sum of 4 quarters · filed 2019-11-12 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | -$22.00K 10-Q · filed 2019-08-12 | -$22.00K derived: sum of 3 quarters · filed 2019-08-12 | -$294.00K derived: sum of 4 quarters · filed 2019-08-12 | |
| 2018-03-31 | -$22.00K 10-Q · filed 2019-05-14 | -$22.00K derived: sum of 2 quarters · filed 2019-05-14 | -$294.00K derived: sum of 3 quarters · filed 2019-05-14 | -$699.00K derived: sum of 4 quarters · filed 2019-05-14 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | -$272.00K derived: sum of 2 quarters · filed 2019-03-26 | -$677.00K derived: sum of 3 quarters · filed 2019-03-26 | $22.00K 10-K · filed 2019-03-26 | |
| 2017-09-30 | -$272.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | -$677.00K derived: sum of 2 quarters · filed 2018-11-14 | $22.00K 10-Q · filed 2018-11-14 | -$22.00K 10-Q · filed 2017-11-13 | |
| 2017-06-30 | -$405.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2018-08-20 | $294.00K 10-Q · filed 2018-08-20 | |||
| 2017-03-31 | $699.00K 10-Q/A · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |